Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/14/2008

For the six months ended June 30, 2008, the gross profit margin was 68.5%, compared to 70.9% for the same period in 2007. This modest decrease reflects the increase in the cost of raw materials while the price at which we sell our products has remained constant.

Selling, general and administrative expenses were $5.1 million for the second quarter of 2008, an increase of 50.2% compared to $3.4 million for the same period in 2007. The selling and administrative expenses as a percentage of sales were 25.9% for the second quarter of 2008 compared to 23.7% for the same period in 2007. For the six months ended June 30, 2008, selling, general and administrative expenses were $8.3 million, an increase of 25.3% compared to $6.7 million in the same period in 2007. For the six months ended June 30, 2008, selling, general and administrative expenses as a percentage of sales was 25.7%, compared to 21.8% for the same period in 2007. This increase was primarily due to increases in general administration costs related to the construction of the Life Resources project, salary and insurance expenses, advertising, research and development expenses and the appreciation of the renminbi.

Tiens continues to strive to expand its market share in China through the branches, chain stores, and Chinese affiliated companies of Tianshi Engineering. To enhance its position in this competitive market, Tianshi Engineering continues to increase its marketing activities in China, including opening additional branches across China, developing a nation-wide advertising campaign, encouraging media coverage and strengthening the Tiens brand.

As of June 30, 2008, Tiens had $86.9 million of retained earnings and total shareholders' equity of $128.3 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "We are pleased with the increase in both domestic and international revenues over last year's second quarter and our sequential growth compared to the first quarter of
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
2. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Yongye Biotechnology International Retains CCG Investor Relations
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
10. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
11. New Book on the Business of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... 2015 Deadly viruses such as Ebola ... of the University City Science Center's Port ... , With a $4.5 million Phase 2 SBIR grant ... Phelix Therapeutics is focused on therapies for unmet ... company is developing first-in-class protease inhibitors based on a ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... Symbol: MSEDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced that the independent Data ... phase III MAESTRO-03 trial of dirucotide in patients with ... recommended that the trial continue as per the protocol. ...
... Therapeutics, Inc., the leader in fragment-based lead discovery ... successful completion of the first phase of its ... of Biogen Idec (Nasdaq: BIIB ). ... to Zenobia,s technology and expertise in structural biology, ...
... Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal 2009 third quarter and nine-month period ended February ... its fiscal year 2009 now ending on February, 28. ... ended February 28, 2009 in the range of $3,400,000 ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... from layers 3.46 billion years old suggests that not only ... atmosphere was as oxygen rich as it is today, according ... ways similar to the way this rock forms around hydrothermal ... have assumed that the hematite in ancient rocks formed by ...
... scientists from the National Institute of Oceanography and the ... research vessel Polarstern. The cooperative project Lohafex has yielded ... has dampened hopes on the potential of the Southern ... 2 ) and thus mitigate global warming. On 17 ...
... a common ingredient in over-the-counter skin creams. Recent results ... it is associated with major environmental risks. , "The ... in the ocean that has a direct impact on ... Porsbring. When Euorpean authorities assess environmental risks, they ...
Cached Biology News:Deep-sea rocks point to early oxygen on Earth 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4Drug used to treat skin conditions is a marine pollutant 2
... ApopTag Fluorescein Direct In Situ ... cells in situ by the ... fragments are tagged with a ... kit provides fluorescence staining for ...
... The CHEMICON APO-BRDU Kit is ... DNA breaks and total cellular DNA to ... The kit contains the instructions and reagents ... positive and negative control cells for assessing ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... FXP is the latest entry in the Biomek ... accuracy and increased robustness, it can meet the ... be configured with either one or two pipetting ... FXP sets the standard for flexible laboratory solutions ...
Biology Products: